Insider Selling: Beta Bionics (NASDAQ:BBNX) CFO Sells 4,896 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 4,896 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $17.03, for a total transaction of $83,378.88. Following the sale, the chief financial officer owned 165,931 shares of the company’s stock, valued at $2,825,804.93. This trade represents a 2.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Feider also recently made the following trade(s):

• On Friday, June 26th, Stephen Feider sold 5,104 shares of Beta Bionics stock. The shares were sold at an average price of $17.05, for a total transaction of $87,023.20.
• On Tuesday, June 2nd, Stephen Feider sold 6,676 shares of Beta Bionics stock. The stock was sold at an average price of $12.61, for a total transaction of $84,184.36.

Beta Bionics Stock Performance

Shares of NASDAQ BBNX traded down $1.33 during mid-day trading on Tuesday, hitting $15.67. 931,657 shares of the stock were exchanged, compared to its average volume of 1,141,549. The company has a market cap of $698.29 million, a P/E ratio of -10.38 and a beta of 3.40. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The stock’s fifty day simple moving average is $12.23 and its two-hundred day simple moving average is $15.41.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%.The business had revenue of $27.63 million for the quarter. As a group, equities research analysts predict that Beta Bionics, Inc. will post -2.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Beta Bionics

Several large investors have recently made changes to their positions in BBNX. Charles Schwab Investment Management Inc. lifted its position in Beta Bionics by 0.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock valued at $10,105,000 after purchasing an additional 931 shares during the period. Deutsche Bank AG grew its position in shares of Beta Bionics by 3.4% during the 4th quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock worth $1,197,000 after buying an additional 1,296 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after buying an additional 1,594 shares during the last quarter. Summit Securities Group LLC bought a new stake in shares of Beta Bionics during the fourth quarter worth approximately $52,000. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after buying an additional 1,818 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BBNX shares. Bank of America cut their price target on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a report on Monday, May 18th. Leerink Partners lowered their price objective on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. Stifel Nicolaus dropped their target price on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Wall Street Zen cut shares of Beta Bionics from a “hold” rating to a “sell” rating in a research note on Sunday, March 29th. Finally, Weiss Ratings lowered shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Beta Bionics presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.70.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.